Maneka Mirchandaney
Stock Analyst at Evercore ISI Group
(0.26)
# 4,377
Out of 5,090 analysts
7
Total ratings
28.57%
Success rate
-28.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maneka Mirchandaney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $41 → $48 | $46.67 | +2.85% | 2 | Sep 11, 2023 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $40 → $30 | $11.50 | +160.87% | 2 | Mar 22, 2023 | |
| INCY Incyte | Downgrades: In-Line | $90 → $78 | $102.52 | -23.92% | 1 | Aug 3, 2022 | |
| VRDN Viridian Therapeutics | Initiates: Outperform | $40 | $32.02 | +24.92% | 1 | Oct 12, 2021 | |
| HOWL Werewolf Therapeutics | Initiates: Outperform | $23 | $0.95 | +2,316.73% | 1 | May 25, 2021 |
Crinetics Pharmaceuticals
Sep 11, 2023
Maintains: Outperform
Price Target: $41 → $48
Current: $46.67
Upside: +2.85%
MiNK Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $40 → $30
Current: $11.50
Upside: +160.87%
Incyte
Aug 3, 2022
Downgrades: In-Line
Price Target: $90 → $78
Current: $102.52
Upside: -23.92%
Viridian Therapeutics
Oct 12, 2021
Initiates: Outperform
Price Target: $40
Current: $32.02
Upside: +24.92%
Werewolf Therapeutics
May 25, 2021
Initiates: Outperform
Price Target: $23
Current: $0.95
Upside: +2,316.73%